SCHEMBL4193993

SCHEMBL4193993

FC(F)(F)c1cc(C(F)(F)F)c2nc(-c3ccc(-c4ncc(Cl)cc4Cl)cc3Cl)[nH]c2c1

nearest known ligand 0.43

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CBFB Q13951 1/20 0.43
CACNA1H O95180 11/20 0.40
CACNA1C Q13936 4/20 0.40
CACNA1B Q00975 3/20 0.40
CACNA1G O43497 4/20 0.40
NPBWR1 P48145 2/20 0.39
TRPV1 Q8NER1 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4193080 0.92 DHODH (0.42) CBFBCACNA1HCACNA1CCACNA1BCACNA1G
SCHEMBL4185871 0.92 CBFB (0.52) CBFBNPBWR1ALDH1A1
SCHEMBL4184828 0.89 CBFB (0.46) CBFBCACNA1HCACNA1CCACNA1BCACNA1G
SCHEMBL4186711 0.86 CBFB (0.53) CBFBNPBWR1ALDH1A1
SCHEMBL16121397 0.85 CACNA1H (0.48) CBFBCACNA1HCACNA1CCACNA1BCACNA1G
SCHEMBL4189049 0.85 CBFB (0.47) CBFBCACNA1HCACNA1CCACNA1BCACNA1G
SCHEMBL4189178 0.85 CBFB (0.50) CBFBCACNA1HCACNA1CCACNA1BCACNA1G
SCHEMBL4180008 0.84 TRPV1 (0.54) CBFBCACNA1HCACNA1CCACNA1BCACNA1G
SCHEMBL4179825 0.83 CBFB (0.50) CBFBNPBWR1ALDH1A1
SCHEMBL4186615 0.83 AURKA (0.52) NPBWR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US claimed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP claimed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US claimed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same TRPV1, TRPA1, BDKRB2 CBFB 1891/4885CACNA1H 522/4885CACNA1C 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.